Daniel Zanchetti, MD
Gastroenterology · New Haven, CTNPI 1821257742
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $75,375 of the $94,150 with a category attached, or 80.1%. AbbVie accounts for 86.9% of it on its own, with 31 other manufacturers making up the rest. Reporting peaked in 2019 at $57,923 and has fallen 96.9% since, to $1,813 in 2025. Among gastroenterology clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 559 payments — averaging $168.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$82K
- Nestle Healthcare Nutrition Inc.$5K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Gilead$740
- Johnson & Johnson$578
- plus $3K from 26 others
What the payments were for
- Consulting fees$1,6632%
- Speaking & faculty fees$75,37580%
- Travel & lodging$6,9447%
- Food & beverage$10,09011%
- Education$780%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 171 | $81,770 |
| Nestle Healthcare Nutrition Inc. | 7 | $5,087 |
| Takeda Pharmaceuticals U.S.A., Inc. | 76 | $1,514 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 72 | $1,241 |
| Gilead | 52 | $740 |
| Johnson & Johnson(2 entities) | 31 | $578 |
| QOL Medical, LLC | 13 | $413 |
| Ardelyx, Inc. | 14 | $321 |
| Bristol Myers Squibb | 14 | $293 |
| Phathom Pharmaceuticals, Inc. | 12 | $276 |
| Ironwood Pharmaceuticals, Inc | 12 | $223 |
| Merck | 10 | $185 |
| Pfizer | 10 | $182 |
| Ferring Pharmaceuticals Inc. | 9 | $149 |
| Redhill Biopharma Inc. | 7 | $113 |
| Braintree Laboratories, Inc. | 5 | $112 |
| Aimmune Therapeutics, Inc. | 4 | $111 |
| Daiichi Sankyo Inc. | 6 | $100 |
| Medtronic | 2 | $99 |
| Alfasigma USA, Inc. | 5 | $92 |
| UCB, Inc. | 6 | $90 |
| Regeneron Healthcare Solutions, Inc. | 3 | $82 |
| Madrigal Pharmaceuticals | 2 | $59 |
| Sanofi | 2 | $51 |
| Evoke Pharma, Inc. | 2 | $50 |
| Celltrion USA Inc. | 3 | $44 |
| Lilly USA, LLC | 2 | $42 |
| Vivus LLC | 2 | $38 |
| Endo Pharmaceuticals Inc. | 2 | $32 |
| Exact Sciences | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Intercept Pharmaceuticals, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$94,150 in reported general payments places this provider in the 95th percentile of 326 gastroenterology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 25 | $117,967 |
| XifaxanRifaximin | 21 | $78,294 |
| LinzessLinaclotide | 74 | $75,677 |
| ZenpepLipase/Protease/Amylase | 14 | $70,341 |
| Mesalamine | 54 | $18,840 |
| MotegrityPrucalopride Succinate | 18 | $15,703 |
| Dexlansoprazole DrDexlansoprazole | 50 | $12,760 |
| TrulancePlecanatide | 11 | $10,436 |
| Lubiprostone | 27 | $6,060 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 99 | $5,853 |
| Emtricitabine-Tenofovir DisopEmtricitabine/Tenofovir (Tdf) | 12 | $5,045 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 30 | $4,864 |
| Sucralfate | 27 | $4,576 |
| Pantoprazole Sodium | 303 | $4,356 |
| Famotidine | 233 | $4,142 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $81,770 | $193,64499 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $1,241 | $88,72932 claims |
| Aimmune Therapeutics, Inc.Zenpep | $111 | $70,34114 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $1,514 | $15,70318 claims |
| Braintree Laboratories, Inc.Sutab | $112 | $4,86430 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 326 gastroenterology providers in Connecticut.
Other gastroenterology in New Haven
- Pramod MistryNew Haven$126K
- Pichamol JirapinyoNew Haven$84K
- Jill GaidosNew Haven$69K
- Myron BrandNew Haven$60K
- Harry AslanianNew Haven$52K
- James BoyerNew Haven$48K
- Thiruvengadam MunirajNew Haven$45K
- Badr Al BawardyNew Haven$42K
- Mae TigheNew Haven$39K
- Priya JamidarNew Haven$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.